No quarterly revenue total was found in Jasper Therapeutics, Inc.'s SEC filings.
Jasper Therapeutics, Inc. (JSPR) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $7.3 million in cash and investments and $270,000 in total debt.
Revenue
—
Net income
$-2.76M
+89.7% vs year-ago quarter
Operating cash flow
$-6.92M
+55.2% vs year-ago quarter
Free cash flow
$-15.46M
EPS
$-0.10
+94.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
33.27M
+104.7% vs year-ago quarter
Net cash
$7.04M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- JSPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1788028
- Former names
- Amplitude Healthcare Acquisition Corp (until Sep 29, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$9.2M | -$11.0M | -$15.8M | -$19.2M | -$27.1M |
| Net income | -$2.8M | -$1.2M | -$9.1M | -$18.7M | -$26.7M |
| Diluted EPS | -$0.10 | -$0.04 | -$0.32 | -$1.13 | -$1.74 |
| Operating cash flow | -$6.9M | -$14.5M | -$21.9M | -$17.0M | -$15.5M |
| Free cash flow | — | — | — | — | -$15.5M |
| Total assets | $11.8M | $21.2M | $35.8M | $57.5M | $46.5M |
| Total liabilities | $10.4M | $17.8M | $31.6M | $45.9M | $23.0M |
| Stockholders' equity | $1.4M | $3.4M | $4.2M | $11.6M | $23.5M |
| Cash and investments | $7.3M | $14.1M | $28.7M | $50.9M | $39.5M |
| Total debt | $270,000 | $757,000 | $1.2M | $1.7M | $2.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Nov 4, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 5, 2026 | Sep 30, 2026 |
| 8-K/A | Amended current report | Oct 5, 2026 | Jul 16, 2026 |
| 8-K/A | Amended current report | Oct 1, 2026 | Jul 16, 2026 |
All 483 Jasper Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.